A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime‐Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA‐BN‐Filo in Healthy Adult Subjects

Trial Profile

A Phase 3, Randomized, Double‐Blind, Placebo‐Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime‐Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA‐BN‐Filo in Healthy Adult Subjects

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Nov 2016

At a glance

  • Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine
  • Indications Ebola virus infections
  • Focus Pharmacodynamics; Registrational
  • Sponsors Crucell Holland
  • Most Recent Events

    • 16 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 09 Sep 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2017.
    • 01 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top